AbbVie: Leiomyoma trials

The registry lists 33 Leiomyoma studies with AbbVie as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 1Phase 2 13Phase 3 14Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenCompletedNCT03886220Phase 4Results posted
• Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenCompletedNCT03271489Phase 3Results posted
• An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedNCT02925494Phase 3Results posted
• An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsTerminatedNCT02811159Phase 2Results posted
• Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)CompletedNCT02691494Phase 3Results posted
• Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenCompletedNCT02654054Phase 3Results posted
• Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine FibroidsCompletedNCT02323646Phase 2Results posted
• A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsCompletedNCT02301897Phase 2Results posted
• A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With LeiomyomasCompletedNCT02147197Phase 3Results posted
• A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With LeiomyomasCompletedNCT02147158Phase 3Results posted
• Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)CompletedNCT01817530Phase 2Results posted
• Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine FibroidsCompletedNCT01451424Phase 2Results posted
• Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine FibroidsCompletedNCT01441635Phase 2Results posted
• Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine FibroidsTerminatedNCT01069120Phase 3Results posted
• An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 ExtTerminatedNCT00958893Phase 2Results posted
• Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003CompletedNCT00958334Phase 2Results posted
• Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00853567Phase 3Results posted
• Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00785356Phase 3Results posted
• Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine FibroidsTerminatedNCT00737282Phase 3Results posted
• Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00735553Phase 3Results posted
• Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00702702Phase 3Results posted
• Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00683917Phase 2Results posted
• A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)WithdrawnNCT06058728
• A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn CapsulesTerminatedNCT05026502
• A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in CanadaWithdrawnNCT04567589
• A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in CanadaWithdrawnNCT04567095
• A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine FibroidsCompletedNCT02580578
• Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200CompletedNCT01739621Phase 2
• Extension of Study ZPV-200CompletedNCT01631903Phase 2
• Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine LeiomyomaWithdrawnNCT01553123Phase 3
• A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic LeiomyomataCompletedNCT01069094Phase 1/2
• Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsCompletedNCT00882258Phase 2
• Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid SymptomsWithdrawnNCT00874302Phase 3